From the *Department of Neurology, Mount Sinai School of Medicine, New York, New York; †Clinique Neurologique, Centre d'investigation Clinique, INSERM U437, Hôpital Guillaume et René Laennec, Nantes, France; ‡Section of Movement Disorders, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois; §Neurologische Klinik der Ruhr-Universitaet Bochum, St.-Josef-Hospital, Bochum, Germany; ||Parkinson's Center of Oregon, National Parkinson Foundation, Department of Neurology, Portland, Oregon; ¶Centre d'Investigation Clinique du CHU de Toulouse, Pavillon Riser, Hôpital Purpan, Toulouse, France; #Neuroscience Department, “ANA ASLAN” Hospital, “N. Gh. Lupu” Hospital, Bucharest, Romania; and **Merck Pharmaceutical KGaA, Darmstadt, Germany.
Preliminary data were reported in abstract form at the 9th International Movement Disorder Society, Miami, Florida.
This study was funded by Merck Pharmaceutical KGaA, Darmstadt, Germany.
Dr. Russ and Dr. Deckers are employees of Merck Pharmaceutical KGaA. Dr. Olanow has served as a consultant to Merck Pharmaceutical KGaA.
Reprints: C Warren Olanow, MD, FRCPC, Department of Neurology, Mount Sinai School of Medicine, Annenberg 14-94, One Gustave L. Levy Place, Box 1137, New York, NY 10029, USA (E-mail:email@example.com).